Nootropic · 2mg × 10 vials
In plain terms: Oxytocin is a research compound - injectable, fast-acting and well studied.
Oxytocin is a 9-amino-acid neuropeptide (Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2, with a disulfide bridge between the two cysteines) produced in the paraventricular and supraoptic nuclei of the hypothalamus and released both into the bloodstream from the posterior pituitary (peripheral hormone function: uterine contraction in labor, milk ejection in lactation) and centrally into the brain (CNS neuromodulator function: pair bonding, trust, social recognition, anxiolysis, sexual response). It signals through a single G-protein-coupled receptor (OXTR) that is densely expressed in the amygdala, hypothalamus, nucleus accumbens, and prefrontal cortex, the circuit that handles social salience, reward, and threat appraisal. The CNS pathway is what nootropic/sexual-health users are after: oxytocin damps amygdala threat response (the social-anxiety-reduction signal), boosts trust and prosocial interpretation of faces, and enhances the affiliative/bonding layer of sexual response without the vascular plumbing focus of PDE5 inhibitors or the desire-circuit focus of PT-141. Peripherally, oxytocin also nudges nitric oxide release in penile tissue, which is the mechanistic basis for the emerging off-label ED literature. The compound has been used as injectable Pitocin/Syntocinon in obstetrics for decades, so the peripheral pharmacology is extremely well characterized. The CNS literature (intranasal trials in autism, social anxiety, PTSD, couples bonding) is newer, smaller, and has known reproducibility debates around how much of an IN dose actually crosses the blood-brain barrier versus signaling via trigeminal/olfactory routes.
Typical dose ranges by experience level - educational reference. Message us and we tailor it to you.
At 1 mg/ml (2 mg vial in 2 ml BAC), 10 IU = ~17 mcg = 0.017 ml = ~2 units on a U-100 syringe. Effect comes on around 20-40 min, peaks around 60-90 min. Subjective signal is calmer, more open, slight warmth in social context. Anyone expecting an MDMA-style rush will be disappointed, oxytocin at peptide-research doses is a soft signal not a strong one. Russian-style fast-onset use (SubQ instead of IN) compresses onset to 20-30 min at the same IU dose.
This is the band most community users settle into. Intranasal 24 IU was the canonical dose in the Andreas Meyer-Lindenberg / Markus Heinrichs trust and amygdala-reactivity trials, so it has the strongest published reference point. Couples-use protocol: both partners dose 30-45 min before time together, layered with PT-141 or paired with a sensate-focus session. Post-MDMA recovery use: 20-30 IU the day after a heavy session to soften the serotonin-depletion crash and rebuild the affiliative state, community-derived but widely reported.
Advanced use is about stack pairing and timing rather than dose escalation. Common advanced patterns: oxytocin + PT-141 for sexual intimacy combos (timed together 30-60 min pre), oxytocin + Selank for layered anxiety with bonding emphasis (Selank for baseline anxiolysis, oxytocin for social/intimate moments), oxytocin + DSIP for evening wind-down and cuddle/sleep stacks, oxytocin + low-dose Cialis for men wanting the desire/connection layer plus vascular assist. SubQ at this band is typically 0.5-1 mg per dose, which is dramatically higher in absolute mcg than IN dosing but matches the bioavailability split (IN is ~10-20% bioavailable, SubQ is ~70-100%).
Straight talk - what people actually report, and what the studies measured.
Peer-reviewed studies and clinical guidelines - tap any to read the source.
foundational trust/social-bonding intranasal trial, 24 IU dose
Read study ↗PubMedDomes et al, Oxytocin attenuates amygdala responses to emotional faces, Biol Psychiatry 2007amygdala-damping mechanism for the social-anxiety effect
Read study ↗PubMedMeyer-Lindenberg et al, Oxytocin and vasopressin in the human brain, Nat Rev Neurosci 2011review of central OXTR signaling and social cognition
Read study ↗PubMedYatawara et al, Effect of oxytocin nasal spray on social responsiveness in autism, Mol Psychiatry 2016pediatric autism trial, 12-week IN protocol, mixed efficacy with strong safety signal
Read study ↗PubMedSippel et al, Oxytocin and PTSD review, Curr Treat Options Psychiatry 2017PTSD adjunctive use, mixed but promising data, particularly for trauma with relational disruption
Read study ↗PubMedBehnia et al, Differential effects of intranasal oxytocin on sexual experiences in heterosexual couples, Horm Behav 2014intimacy/sexual-experience trial in couples, the canonical intimacy-enhancement reference
Read study ↗Aggregated sentiment from public forums & socials - real-world reports, not individual endorsements.
Most-reported effect (positive): subtle calm, warmth, easier eye contact, lowered social-threat reactivity. Many users describe it as "I felt softer with my partner", "easier to be present", "small lift" rather than a strong drug signal.
Effect duration debate: this is the loudest community divergence from the literature. Published IN trials describe a ~30-90 min central window. Community users frequently report subjective effect 2-4 hours, others report nothing at all, others report a clear effect only with SubQ not IN.
- Divergence: literature says reliable subjective effect at 20-40 IU IN, community reports a non-trivial "I felt nothing" responder rate (~20-30% of first-timers), suspected drivers are storage degradation (oxytocin is fragile), nasal absorption variability, expectation effects, and the inherent gentleness of the signal.
Sleepiness / mild sedation: common at 30-40 IU IN, especially evening dosing. Some users specifically dose for this effect (sleep stacks) and others find it inconvenient daytime.
Headache: occasional, mostly at higher SubQ doses
Emotional flatness / "meh" the next day: reported by a minority, particularly after high-dose or back-to-back-day use
Route: intranasal (community standard for social/bonding/anxiety use), SubQ injection (faster onset, used for intimacy/ED off-label), sublingual troche (compounded pharmacy preparation, slower onset)
Storage: refrigerated, stable ~14-21 days reconstituted. This is shorter than most peptides, oxytocin is genuinely fragile in aqueous solution and degrades faster at room temp. Lyophilized vials room-temp short-term, refrigerate for long storage. Freezing in single-use aliquots extends usable life past 30 days for low-frequency users.
Notes: Systemic plasma half-life is famously short (~3-5 minutes), which is why obstetric Pitocin is run as a continuous IV drip. For peptide-research use the central effect window is the part that matters, ~30-90 minutes post intranasal dose. This is also why "frequent dosing" in this product means "redose 30-60 min before each intended event", not "maintain steady serum levels". Do not blow nose for 10-15 minutes after IN dosing.